€ 29.00
Endogenic ARA 290 5 mg is an innovative peptide that can be an excellent way to fight chronic pain. It is also a strong support for muscles, but also a natural anti-inflammatory effect that helps reduce inflammation resulting from intense exercise. Thanks to ARA 290, you will regain energy and motivation for further challenges, and your body will thank you for faster regeneration. Try the peptide when you are fighting chronic pain and regain the desire for strong training!
ARA-290 is a small peptide molecule derived from the modification of erythropoietin (EPO) – a hormone responsible for regulating the production of red blood cells (erythrocytes) in the human body. Although EPO is primarily associated with stimulating erythropoiesis, scientists have discovered that modified fragments of this hormone can exert an anti-inflammatory and protective effect on tissues affected by various disease processes.
INTENDED FOR RESEARCH PURPOSES!
All of the above-mentioned properties are observed in laboratory tests, not performed on humans, they are for informational purposes only. All information contained in the descriptions has not been approved by GIS, GIF or EFSA. The substance is not a medicine, food product or dietary supplement, and consequently it is not suitable for human consumption. The product qualifies as a chemical reagent / reference material permitted for marketing in the EU. It can only be used for scientific research. Other information about the product is included in the chemical safety data sheet, which we make available for review. The products are available only to institutions or individuals who have been associated with research or laboratory activities.
The key property of ARA 290 is its ability to stimulate the Innate Repair Receptor (IRR). Although classic erythropoietin can also interact with various receptors, it is the modified EPO fragments, such as ARA 290, that can selectively activate signaling pathways aimed at protecting and regenerating tissues.
ARA 290 is of particular interest to scientists and clinicians due to its neuroprotective potential. Numerous studies indicate that this peptide may support the rebuilding of myelin sheaths in damaged nerves, which is important in the treatment of various neuropathies, including diabetic neuropathy.
One of the most promising applications of ARA 290 is the treatment of diabetic neuropathy, a disease that is a complication of long-term high blood glucose levels. This neuropathy manifests itself through damage to peripheral nerves, which leads to:
Studies on ARA 290suggest that this peptide may:
In the case of chronic kidney disease (CKD), it is crucial to inhibit inflammation and prevent progressive damage to renal tissue. ARA 290, thanks to its anti-inflammatory effect, can help protect the renal parenchyma. Some studies indicate that the use of this peptide:
Because of itsneuroprotective and anti-inflammatory properties,ARA 290is also of interest in the context of:
In inflammation, cytokines such as interleukins (IL-1, IL-6) or tumor necrosis factor (TNF-α) play a key role. Chronic inflammation can lead to disease progression and damage to nerve tissue, kidneys, and other organs. ARA 290</span style=”font-weight: 400;”> by activating the IRR receptor</span style=”font-weight: 400;”> inhibits excessive secretion of pro-inflammatory cytokines, alleviating the harmful effects of the long-term inflammatory process.
Many patients with diabetic neuropathy or chronic kidney disease struggle with deterioration of blood flow in small vessels, which additionally increases the risk of tissue damage.
ARA 290 has a positive effect on the functioning of the endothelium, which may bring benefits in the form of:
Due to the anti-inflammatory activity of ARA 290, research is underway to use it in the treatment of autoimmune diseases, including Sjögren’s syndrome. This condition involves the autoaggression of the immune system against its own salivary and lacrimal glands, which leads to symptoms of dry mucous membranes and eyes. Reducing inflammatory activity with ARA 290 could potentially alleviate the disease.
Researchers are also considering using ARA 290 inacute spinal cord injury where a complex inflammatory response and neuronal destruction occur. There are reports that ARA 290 may protect neurons and stimulate regenerative processes, although this is still an area that requires further clinical research.
Doses usually range from 2 mg to 10 mg per day or every few days, depending on the indications.
Another method is a dosage similar to TB-500, e.g. 2 mg twice a week.
ARA 290 is a small peptide molecule created by modification of erythropoietin (EPO), with anti-inflammatory and neuroprotective effects. Due to its ability to selectively activate the IRR receptor, this peptide may help protect tissues from further damage and support repair processes. The results of studies in the area of diabetic neuropathy and chronic kidney disease are particularly promising, although the range of potential applications is much wider.
Previous reports indicate that ARA 290:
Reviews
There are no reviews yet.